GlaxoSmithKline Plc’s cancer treatment Zejula met the main goal of helping patients with ovarian cancer live longer without their disease worsening says a late-stage study. The study, called PRIMA, tested the treatment as maintenance therapy in women who have undergone platinum-based chemotherapy and met the main goal for women regardless of their biomarker status, GSK said. For GSK, the success of Zejula would help it access a wider population group and give it an edge over rival PARP inhibitors such as AstraZeneca and Merck & Co’s Lynparza and Clovis Oncology’s Rubraca.
Reuters
